Literature DB >> 25112605

Adverse reactions to biologic agents and their medical management.

Onur Boyman1, Denis Comte2, François Spertini2.   

Abstract

Biologic agents have substantially advanced the treatment of immunological disorders, including chronic inflammatory and autoimmune diseases. However, these drugs are often associated with adverse events (AEs), including allergic, immunological and other unwanted reactions. AEs can affect almost any organ or system in the body and can occur immediately, within minutes to hours, or with a delay of several days or more after initiation of biologic therapy. Although some AEs are a direct consequence of the functional inhibition of biologic-agent-targeted antigens, the pathogenesis of other AEs results from a drug-induced imbalance of the immune system, intermediary factors and cofactors, a complexity that complicates their prediction. Herein, we review the AEs associated with biologic therapy most relevant to rheumatic and immunological diseases, and discuss their underlying pathogenesis. We also include our recommendations for the medical management of such AEs. Increased understanding and improved risk management of AEs induced by biologic agents will enable better use of these versatile immune-response modifiers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25112605     DOI: 10.1038/nrrheum.2014.123

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  209 in total

1.  Rituximab-induced leukocytoclastic vasculitis: a case report.

Authors:  Praveen Kandula; Peter A Kouides
Journal:  Arch Dermatol       Date:  2006-02

2.  Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

Authors:  John H Stone; Janet T Holbrook; Matthew A Marriott; Andrea K Tibbs; Lourdes P Sejismundo; Y-I Min; Ulrich Specks; Peter A Merkel; Robert Spiera; John C Davis; E William St Clair; W Joseph McCune; Steven R Ytterberg; Nancy B Allen; Gary S Hoffman
Journal:  Arthritis Rheum       Date:  2006-05

3.  Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy Fleischmann; Daniel E Furst; Katherine Macey; Marianne Sweetser; Ariella Kelman; Ravi Rao
Journal:  J Rheumatol       Date:  2010-01-28       Impact factor: 4.666

4.  Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.

Authors:  Elizabeth C Hsia; John J Cush; Eric L Matteson; Anna Beutler; Mittie K Doyle; Benjamin Hsu; Stephen Xu; Mahboob U Rahman
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-02       Impact factor: 4.794

5.  Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.

Authors:  Joan T Merrill; Ellen M Ginzler; Daniel J Wallace; James D McKay; Jeffrey R Lisse; Cynthia Aranow; Frank R Wellborne; Michael Burnette; John Condemi; Z John Zhong; Lilia Pineda; Jerry Klein; William W Freimuth
Journal:  Arthritis Rheum       Date:  2012-10

6.  Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure.

Authors:  Mark C Genovese; Andrea Rubbert-Roth; Josef S Smolen; Joel Kremer; Majed Khraishi; Juan Gómez-Reino; Anthony Sebba; Robert Pilson; Sarah Williams; Ronald Van Vollenhoven
Journal:  J Rheumatol       Date:  2013-03-01       Impact factor: 4.666

7.  Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

Authors:  A Vultaggio; A Matucci; F Nencini; S Pratesi; P Parronchi; O Rossi; S Romagnani; E Maggi
Journal:  Allergy       Date:  2009-11-27       Impact factor: 13.146

8.  Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.

Authors:  John Kuruvilla; Heather A Leitch; Linda M Vickars; Paul F Galbraith; Charles H Li; Saad Al-Saab; Sheldon C Naiman
Journal:  Eur J Haematol       Date:  2003-11       Impact factor: 2.997

Review 9.  B cell non-Hodgkin's lymphoma: rituximab safety experience.

Authors:  Ann Mohrbacher
Journal:  Arthritis Res Ther       Date:  2005-05-18       Impact factor: 5.156

10.  Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.

Authors:  J Seneschal; B Milpied; B Vergier; S Lepreux; T Schaeverbeke; A Taïeb
Journal:  Br J Dermatol       Date:  2009-06-05       Impact factor: 9.302

View more
  30 in total

Review 1.  Optimizing treatment in paediatric rheumatology--lessons from oncology.

Authors:  Tim Niehues
Journal:  Nat Rev Rheumatol       Date:  2015-04-21       Impact factor: 20.543

Review 2.  [Personalized medicine in allergology].

Authors:  W Pfützner; J Pickert; C Möbs
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

Review 3.  Cutaneous Manifestations of Reactions to Biologics.

Authors:  Iris M Otani; Amy S Levin; Aleena Banerji
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-21       Impact factor: 4.806

Review 4.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

5.  Stop Being So Sensitive: An Exceptionally Rare Report of Ustekinumab-Induced Sub-acute Hypersensitivity Pneumonitis.

Authors:  Azka Ali; Jason Chertoff; Christopher Harden; Dara Wakefield; James Wynne
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-09-15

Review 6.  Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease.

Authors:  Maria Gabriella Matera; Clive Page; Paola Rogliani; Luigino Calzetta; Mario Cazzola
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

7.  Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India.

Authors:  S Chandrashekara; Vineeta Shobha; Vijay Rao; Anu Desai; Ramesh Jois; B G Dharmanand; Sharath Kumar; Pradeep Kumar; Chethana Dharmapalaiah; Kurugodu Mathada Mahendranath; Shiva Prasad; Manisha Ashwin Daware; Yogesh Singh; Uma Karjigi; S Nagaraj; K R Anupama
Journal:  Rheumatol Int       Date:  2019-01-25       Impact factor: 2.631

8.  The Efficacy and Evidence-Based Use of Biologics in Children and Adolescents: Using Monoclonal Antibodies and Fusion Proteins as Treatments.

Authors:  Tim Niehues; Tuba Turul Özgür
Journal:  Dtsch Arztebl Int       Date:  2019-10-18       Impact factor: 5.594

9.  Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients.

Authors:  Ilana Reinhold; Sena Blümel; Jens Schreiner; Onur Boyman; Jan Bögeholz; Marcus Cheetham; Gerhard Rogler; Luc Biedermann; Michael Scharl
Journal:  Inflamm Intest Dis       Date:  2020-11-20

10.  An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients.

Authors:  Hamid Asadzadeh Aghdaei; Azade Amini Kadijani; Dario Sorrentino; Alireza Mirzaei; Shabnam Shahrokh; Hedieh Balaii; Marco Geraci; Mohammad Reza Zali
Journal:  United European Gastroenterol J       Date:  2018-05-02       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.